Hospital
San Ramon Regional Medical Center, LLC
San Ramon Regional Medical Center, LLC was paid $2.88M by Medicaid between Jan 2018 and Dec 2024, across 77 billing codes. Its largest line is 0450, Emergency room services — 18% of everything it billed.
33Billing provider infoSAN RAMON REGIONAL MEDICAL CENTER, LLC
SAN RAMON, CA 94583
SAN RAMON, CA 94583
33aNPI1932131489assigned 07/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.88M
24GClaims102,946
24DCodes billed77
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#248 of 410
Median peer was paid$6.90M
This provider vs. median0.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 13,714 | $362K | |
| 2019 | 11,435 | $284K | |
| 2020 | 6,843 | $174K | |
| 2021 | 12,269 | $317K | |
| 2022 | 18,350 | $580K | |
| 2023 | 19,790 | $541K | |
| 2024incomplete | 20,545 | $624K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 18% | 10,243 | 9,021 | $513K |
| J3490 | Unclassified drugs | 9.4% | 6,457 | 4,189 | $269K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.8% | 3,822 | 3,330 | $224K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.3% | 2,797 | 2,597 | $152K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.4% | 2,188 | 2,149 | $128K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.4% | 522 | 507 | $128K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 4.1% | 2,466 | 2,428 | $117K |
| 96375 | Therapeutic injection; each additional sequential IV push | 4.0% | 2,562 | 2,291 | $115K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.5% | 4,301 | 3,943 | $99K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.2% | 877 | 856 | $94K |
| 99199 | Unlisted special service, procedure or report | 3.2% | 1,829 | 1,627 | $91K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.1% | 693 | 657 | $90K |
65 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 2.3% | 2,523 | $67K |
| 99070 | 2.1% | 1,658 | $61K | |
| 0272 | 2.0% | 933 | $56K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.7% | 243 | $49K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.6% | 5,141 | $47K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 7,506 | $46K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 3,614 | $44K |
| J7030 | Infusion, normal saline solution , 1000 cc | 1.3% | 3,626 | $38K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.3% | 1,451 | $36K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 1.2% | 1,069 | $35K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 1,267 | $33K |
| 80053 | Comprehensive metabolic panel | 1.1% | 2,301 | $30K |
| 84484 | <1% | 2,918 | $28K | |
| 80076 | <1% | 3,371 | $27K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 464 | $25K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 411 | $24K |
| 83880 | <1% | 1,055 | $22K | |
| 99285 | Emergency room visit (most serious) | <1% | 226 | $21K |
| 83690 | <1% | 3,058 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,730 | $16K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 120 | $15K |
| 84703 | <1% | 2,274 | $13K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 275 | $12K |
| 83605 | <1% | 1,438 | $12K | |
| 81000 | <1% | 3,839 | $11K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,449 | $10K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,377 | $8K |
| 83735 | <1% | 1,266 | $6K | |
| 87040 | <1% | 516 | $5K | |
| 87430 | <1% | 609 | $5K | |
| 87070 | <1% | 491 | $5K | |
| 0636 | <1% | 260 | $3K | |
| 85379 | <1% | 388 | $3K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 340 | $3K |
| 86140 | <1% | 454 | $3K | |
| 85610 | <1% | 891 | $3K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 115 | $2K |
| 0011A | <1% | 57 | $2K | |
| 85730 | <1% | 406 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 124 | $1K |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 52 | $954.76 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 26 | $830.65 |
| 82550 | <1% | 191 | $828.48 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 93 | $745.23 |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 15 | $733.52 |
| 87420 | <1% | 83 | $665.55 | |
| A9270 | Non-covered item or service | <1% | 50 | $555.25 |
| 94664 | <1% | 43 | $504.88 | |
| Z7502 | <1% | 13 | $489.80 | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 12 | $461.01 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 29 | $459.59 |
| 99283 | Emergency room visit (moderate) | <1% | 19 | $430.48 |
| 0250 | <1% | 30 | $403.00 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 18 | $362.53 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 26 | $280.97 |
| 0270 | <1% | 101 | $250.63 | |
| 82962 | <1% | 88 | $247.15 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $232.65 |
| 87186 | <1% | 25 | $186.97 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 30 | $155.87 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $135.43 |
| 82553 | <1% | 13 | $134.32 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,879 | $132.24 |
| 87077 | <1% | 25 | $73.58 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 46 | $2.21 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHADHA, BEENU (CFO)